


## AMENDMENTS TO AND LISTING OF CLAIMS

Kindly amend the Claims as follows:


1. (Currently amended) A compound of formula I:




wherein

R<sub>1</sub> is a residue of formula (a), (b) or (c)


(a)



(b)



(c)



R<sub>2</sub> is  $-(CR_{22}R_{23})_{1-3}-$  or  $-C(O)-$ ;

each of R<sub>3</sub> and R<sub>8</sub> independently is S;

each of R<sub>4</sub> and R<sub>5</sub>, independently, is optionally R<sub>25</sub>-substituted C<sub>3</sub>-C<sub>12</sub>-cycloalkyl, C<sub>1</sub>-C<sub>12</sub>-alkyl or saturated C<sub>8-12</sub>-polycyclic residue; or optionally R<sub>26</sub>- and/or R<sub>27</sub>-substituted aryl, arylC<sub>1-4</sub>-alkyl or heteroaryl; ~~wherein up to 4 carbon atoms of R<sub>4</sub> and/or R<sub>5</sub> are optionally substituted by S, O or NR<sub>24</sub>;~~

R<sub>6</sub> is H; C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>3</sub>-C<sub>6</sub>-cycloalkyl; or optionally R<sub>26</sub>- and/or R<sub>27</sub>-substituted aryl, arylC<sub>1-4</sub>-alkyl or heteroaryl;

R<sub>7</sub> is CR<sub>28</sub> or N;

R<sub>9</sub> is a direct bond; ~~(CR<sub>22</sub>R<sub>23</sub>)<sub>1-2</sub>~~; or NR<sub>24</sub>;

each of R<sub>10-23</sub>, R<sub>16</sub>, R<sub>17</sub>, R<sub>18</sub>, R<sub>19</sub>, R<sub>20</sub>, R<sub>21</sub>, and R<sub>28</sub>, independently, is H; F; Cl; Br; C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>2</sub>-C<sub>6</sub>-alkoxyalkyl; C<sub>1</sub>-C<sub>6</sub>-halogenoalkyl; C<sub>3</sub>-C<sub>6</sub>-cycloalkyl; optionally R<sub>26</sub>- and/or R<sub>27</sub>-substituted aryl or heteroaryl; CONR<sub>29</sub>R<sub>30</sub>; COOR<sub>29</sub>; CN; NO<sub>2</sub>; or OR<sub>31</sub>; or

~~two of R<sub>10-19</sub> which are attached to the same carbon atom, together with the carbon atom to which they are attached, form a 3-7 membered nonaromatic ring optionally containing up to two heteroatoms selected independently from N, O and S; or R<sub>17</sub> and R<sub>18</sub> together with the C atoms to which they are attached, form a 4-7 membered nonaromatic ring optionally containing up to two heteroatoms selected independently from N, O and S; or~~

~~R<sub>20</sub> and R<sub>24</sub>, together with the carbon atoms to which they are attached, form an optionally R<sub>26</sub>- and/or R<sub>27</sub>-substituted aryl or heteroaryl;~~

each of R<sub>24</sub>-R<sub>29</sub> and R<sub>30</sub>, independently, is H; C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>2</sub>-C<sub>6</sub>-alkoxyalkyl; C<sub>1</sub>-C<sub>6</sub>-halogenoalkyl; C<sub>3</sub>-C<sub>7</sub>-cycloalkyl; or optionally R<sub>26</sub>- and/or R<sub>27</sub>-substituted aryl, arylC<sub>1-4</sub>-alkyl or heteroaryl;

R<sub>25</sub> represents 1-to-4 substituents each, independently, H; F; Cl; Br; C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>2</sub>-C<sub>6</sub>-alkoxyalkyl; C<sub>1</sub>-C<sub>6</sub>-halogenoalkyl; C<sub>3</sub>-C<sub>6</sub>-cycloalkyl; optionally R<sub>26</sub>- and/or R<sub>27</sub>-substituted aryl or heteroaryl; CONR<sub>29</sub>R<sub>30</sub>; COOR<sub>29</sub>; CN; NO<sub>2</sub>; or OR<sub>31</sub>

~~having one of the significances given for R<sub>10-23</sub> above;~~

R<sub>26</sub> represents 1-to-4 substituents each, independently, selected from C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>1</sub>-C<sub>6</sub>-hydroxyalkyl; C<sub>2</sub>-C<sub>6</sub>-alkoxyalkyl; C<sub>1</sub>-C<sub>6</sub>-halogenoalkyl; C<sub>3</sub>-C<sub>6</sub>-cycloalkyl; C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>3</sub>-C<sub>6</sub>-cycloalkenyl; C<sub>2</sub>-C<sub>6</sub>-alkynyl; aryl; heteroaryl; heteroaryl N-oxide; F; Cl; Br; I; OH; OR<sub>4</sub>; CONH<sub>2</sub>; CONHR<sub>4</sub>; CONR<sub>4</sub>R<sub>4</sub>; OC(O)R<sub>4</sub>; OC(O)OR<sub>4</sub>; OC(O)NHR<sub>4</sub>; OC(O)NR<sub>4</sub>R<sub>4</sub>; OSO<sub>2</sub>R<sub>4</sub>; COOH; COOR<sub>4</sub>; CF<sub>3</sub>; CHF<sub>2</sub>; CH<sub>2</sub>F; CN; NO<sub>2</sub>; NH<sub>2</sub>; NHR<sub>4</sub>; NR<sub>4</sub>R<sub>4</sub>; NHC(O)R<sub>4</sub>; NR<sub>4</sub>C(O)R<sub>4</sub>; NHC(O)NHR<sub>4</sub>; NHC(O)NH<sub>2</sub>; NR<sub>4</sub>C(O)NHR<sub>4</sub>; NR<sub>4</sub>C(O)NR<sub>4</sub>R<sub>4</sub>; NHC(O)OR<sub>4</sub>; NR<sub>4</sub>C(O)OR<sub>4</sub>; NH<sub>2</sub>SO<sub>2</sub>R<sub>4</sub>; N(SO<sub>2</sub>R<sub>4</sub>)<sub>2</sub>; NR<sub>4</sub>SO<sub>2</sub>R<sub>4</sub>; SR<sub>4</sub>; S(O)R<sub>4</sub>; SO<sub>2</sub>R<sub>4</sub>; Si(CH<sub>3</sub>)<sub>3</sub> and B(OC(CH<sub>3</sub>)<sub>2</sub>)<sub>2</sub>;

R<sub>27</sub> represents two adjacent substituents which form an annulated 4-7-membered nonaromatic ring optionally containing up to two heteroatoms selected,

independently, from N, O and S;

R<sub>31</sub> is C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>3</sub>-C<sub>7</sub>-cycloalkyl; optionally R<sub>26</sub>- and/or R<sub>27</sub>-substituted aryl, arylC<sub>1-4</sub>-alkyl or heteroaryl; or CF<sub>3</sub>;

or a pharmaceutically-acceptable salt thereof.

2. (Currently amended) A compound according to Claim 1, which is selected from 1,3-dicyclohexyl-2-(5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea, 1-cyclohexyl-3-cyclopentyl-2-(5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea, 1-cycloheptyl-3-cyclohexyl-2-(5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea, 1,3-dicycloheptyl-2-(5,6-dihydroimidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea, 1-cyclohexyl-3-cyclooctyl-2-(5,6-dihydroimidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea, 1,3-dicyclohexyl-2-(6,6-dimethyl-5,6-dihydroimidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea, 1,3-dicyclooctyl-2-(5,6-dihydro[(-)]imidazo[2,1b]thiazol-3-ylmethyl)-isothiourea and 1,3-dicycloheptyl-2-(6,6-dimethyl-5,6-dihydroimidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea.

3. (Currently amended) A pharmaceutical composition comprising a compound according to Claim 1 in free form or in a pharmaceutically-acceptable salt form in ~~association with~~ and a pharmaceutically-acceptable diluent or carrier therefor.


4. (Currently amended) A method for prevention or treatment of disorders or diseases mediated by interactions between chemokine receptors, acute or chronic transplant rejection, inflammatory diseases, autoimmune diseases or proliferative diseases comprising administering to a subject in need thereof a therapeutically-effective amount of the compound of Claim 1.

5. (Currently amended) A method for prevention or treatment of tumor invasiveness, symptoms associated with tumor growth, metastatic spread of tumours, tumor-associated angiogenesis or growth of micrometastases comprising administering to a subject in need thereof a therapeutically-effective

amount of the compound of Claim 1.

6. (Currently amended) A method for prevention or treatment of an infectious disease comprising administering to a subject in need thereof a therapeutically-effective amount of the compound of Claim 1.

7. (Currently amended) A process for preparing a compound of formula I according to Claim 1 comprising reacting a compound of formula II



with a compound of formula III



wherein  $R_1$  to  $R_6$  are as defined in Claim 1, and  $R_{32}$  is a leaving group; and optionally converting ~~[[a]]~~ the resultant compound of formula I obtained in free form to a salt form or *vice versa*.

8. (Currently amended) A pharmaceutical combination comprising a compound according to Claim 1 in free form or in a pharmaceutically-acceptable salt form and a further agent selected from immunosuppressive, immunomodulating, anti-inflammatory, antiproliferative, antineoplastic, chemotherapeutic, anti-infective, anti-viral, and antibiotic agents, and agents for the treatment of acute myeloid leukemia.

9. (Currently amended) The pharmaceutical combination according to Claim 8 comprising an antiretroviral agent, ~~in particular an anti-HIV agent.~~

10. (Currently amended) ~~Use of a combination according to claim 9 for the manufacture of a medicament for~~ A method of preventing or combating an infectious disease, in particular viral infection or progression of AIDS in a subject comprising administering to that subject a pharmaceutical combination according to Claim 9.

11. (Currently amended) A method of treatment or prevention of any of the following conditions:

- i) disorders or diseases mediated by interactions between chemokine receptors,
- ii) acute or chronic transplant rejections,
- iii) inflammatory or autoimmune diseases,
- iv) proliferative diseases,
- v) symptoms associated with tumor invasiveness or tumor growth,
- vi) metastatic spreads of tumours, tumor-associated angiogenesis and growths of micrometastases,
- vii) an infectious diseases disease, ~~in particular viral infections,~~ comprising administering to ~~said a~~ a subject a therapeutically-effective amount of a compound according to Claim 1, or a ~~or a~~ pharmaceutically-acceptable salt thereof, or a pharmaceutical composition comprising a compound according to Claim 1 in free form or in a pharmaceutically-acceptable salt form in association with a pharmaceutically-acceptable diluent or carrier therefor.

12. (Currently amended) The method of Claim 6, wherein said infectious disease is a viral infection.

13. (Currently amended) The method of Claim 12, wherein said viral infection is AIDS.

14. (Currently amended) The method of Claim 11, wherein the ~~condition~~

infectious disease is a viral infection.

15. (Currently amended) The method of Claim 14, wherein said viral infection is AIDS.

16. (New) The pharmaceutical combination according to Claim 9, wherein the antiretroviral agent is an anti-HIV agent.

17. (New) The method according to Claim 10, wherein the infectious disease is a viral infection or progression of AIDS.